SarahStar
Posted - 2 hours ago
MYNZ I don't give a damn about bots, I trust this stock 100000000%. Deal with Thermo Fisher Healthcare Giant is a huge credibility. 1/ German gov stake 10% 2/ Thermo Fisher partnership 3/ Frankie Muniz Malcolm in the Middle support 4/ Petra Starke former WH senior advisor of Obama 5/ 75M patients coverage in EU + 9labs 6/ 88% pre-cancer results unlike competitors EXAS 43% and GH 13%. 7/ RS will be cancelled 🤞extension of 180 days by nasdaq? 8/ 30M shares offering deal, TMO will get that? Wtf are you waiting for ??? Crush this shorties 🔥🚀 $PHVS $PRAX
JordanBall
Posted - 1 day ago
$PHVS $PRAX LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?
Andrea_Stephens
Posted - 2 days ago
MYNZ: Who’s Next After TMO? 🚀 🔥 LabConnect: Central lab for clinical trials—big potential clients. 🌍 Genova Diagnostics: 50+ countries, serving healthcare pros globally. 🔬 ACM Global: Central lab player for clinical trials—big reach. 🏥 ARUP: Trusted by U.S. hospitals and clinics nationwide. 🩺 Mayo Clinic Labs: Partners with 4,000+ global healthcare orgs. 💡 Quest Diagnostics: Serves ~50% of U.S. hospitals & doctors. 🌐 Labcorp: Massive global network in 100+ countries. 🔗 OPKO/BioReference: Multinational lab powerhouse. 📊 Sonic Healthcare: Global diagnostics + radiology leader. ⚡ BioReference: 12M+ tests/year across U.S. facilities. 🚀 TMO is already on board ($210B market cap)—who’s next? LET’S GOOO! 💥 $PHVS $PRAX $INVA
King_S
Posted - 2 weeks ago
MYNZ moving +12.25% in PM and opening climbing up same with volume 🚀 All is buying, ready for the squeeze. HUGE PR drop incoming before the Nov 13 meeting, so compliance is coming, no RS needed. $PHVS $PRAX $INVA
PenkeTrading
Posted - 10/22/24
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Pharvaris BV. Is that bullish or bearish? $PHVS #RsiOverbought #NASDAQ
jParkz
Posted - 2 months ago
$PHVS News Article Pharvaris Provides Business Update and Expands Development Program for Deucrictibant https://marketwirenews.com/news-releases/pharvaris-provides-business-update-and-expands-devel-5300683212351037.html $PHVS
Stock_Titan
Posted - 2 months ago
$PHVS Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
https://www.stocktitan.net/news/PHVS/pharvaris-provides-business-update-and-expands-development-program-24yjbkn1ekuq.html
Stock_Titan
Posted - 2 months ago
$PHVS Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
https://www.stocktitan.net/news/PHVS/pharvaris-presents-deucrictibant-long-term-extension-data-for-both-z3y8fdkelrln.html
Stock_Titan
Posted - 2 months ago
$PHVS Pharvaris Presents Data at the Bradykinin Symposium 2024
https://www.stocktitan.net/news/PHVS/pharvaris-presents-data-at-the-bradykinin-symposium-f0qboai2wwk4.html
Stock_Titan
Posted - 08/28/24
$PHVS Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
https://www.stocktitan.net/news/PHVS/deucrictibant-clinical-real-world-nonclinical-and-discovery-data-to-09kccszzvxoj.html
Stock_Titan
Posted - 3 months ago
$PHVS Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
https://www.stocktitan.net/news/PHVS/pharvaris-reports-second-quarter-2024-financial-results-and-provides-zwz03zmxtccb.html
STOCKWIZARD22
Posted - 3 months ago
$PHVS
DonCorleone77
Posted - 4 months ago
$BIIB $PHVS $VRDN $EWTX Wedbush reveals three potential buyout targets for Biogen Wedbush identified potential acquisitions that might be a good fit for Biogen (BIIB) by screening the public biotech universe for companies in at least Phase 2 with market caps between $500M and $4B. After filtering on therapeutic focus, Wedbush's "short" list of candidates reveals several opportunities even outside traditional central nervous companies, the analyst tells investors in a research note. Within the firm's own coverage universe, it believes Pharvaris (PHVS), Viridian Therapeutics (VRDN) and Edgewise Therapeutics (EWTX) are "interesting" potential Biogen acquisition targets. It points out that Biogen management has indicated the company holds capacity for an additional $8B-$10B in transactions over the next two years. Wedbush has a Neutral rating on Biogen with a $215 price target.
Stock_Titan
Posted - 5 months ago
$PHVS Pharvaris Announces Annual Meeting of Shareholders
https://www.stocktitan.net/news/PHVS/pharvaris-announces-annual-meeting-of-k1i5ohvop7it.html
DonCorleone77
Posted - 5 months ago
$PHVS Pharvaris' deucrictibant shows positive results in HAE attack prevention Pharvaris presented data highlighting the pharmacological and clinical properties of deucrictibant for the treatment and prevention of HAE attacks at the 20th Annual Congress of International Drug Discovery Science and Technology, the 2024 Eastern Allergy Conference and the European Academy of Allergy and Clinical Immunology Congress 2024. In post-hoc analyses of the Phase 2 RAPIDe-1 clinical study data, resolution of HAE symptoms follow treatment with deucrictibant immediate-release capsule and placebo were measured. Treatment with a single dose of oral deucrictibant resulted in the majority of HAE attacks achieving substantial symptom resolution - 78.6% of participants with deucrictibant 20 mg vs. 22.4% of placebo within 24 hours. Evaluation of Treatment Satisfaction Questionnaire for Medication in participants in the Phase 2 CHAPTER-1 clinical study showed satisfaction with the effectiveness of deucrictibant is higher to placebo and is in-line with separate observations of high-efficacy injectables, while numerically more favorable than separate observations with other oral prophylactic therapies. The side effects and convenience subdomain scores were consistent between deucrictibant and placebo.
Stock_Titan
Posted - 5 months ago
$PHVS Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
https://www.stocktitan.net/news/PHVS/pharvaris-highlights-properties-of-deucrictibant-in-data-kp8ny563y14y.html
Stock_Titan
Posted - 6 months ago
$PHVS Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
https://www.stocktitan.net/news/PHVS/pharvaris-to-present-clinical-and-nonclinical-data-at-upcoming-n48dflgrsg5x.html
Stock_Titan
Posted - 6 months ago
$PHVS Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
https://www.stocktitan.net/news/PHVS/pharvaris-reports-first-quarter-2024-financial-results-and-provides-pnfks25ghsmp.html
Doozio
Posted - 6 months ago
$PHVS nope it started da end of month FOUR! Faatch 💣 or 🧠⏰🌙 wen da huckleberries r below da $$$
Thestocktraderhubzee
Posted - 04/23/24
WATCHLIST APR 23 2024..
$SLB Morgan Stanley Maintains Overweight on Schlumberger, Maintains $65 Price Target
$PHVS Morgan Stanley Maintains Overweight on Pharvaris, Maintains $34 Price Target
$KBR Citigroup Maintains Buy on KBR, Raises Price Target to $72
$ACM Citigroup Maintains Buy on AECOM, Raises Price Target to $116
$WTFC Citigroup Maintains Buy on Wintrust Finl, Lowers Price Target to $113
DonCorleone77
Posted - 7 months ago
$PHVS Pharvaris files automatic mixed securities shelf
DonCorleone77
Posted - 7 months ago
$PHVS 2 of 2 - Pharvaris reports Q4 EPS (EUR 0.74) vs. (EUR 1.16) last year ....We are pleased with the HAE community's excitement in RAPIDe-3, which is enrolling as planned; we will provide the anticipated timing of topline data as enrollment progresses and data is accumulated. Receipt of the Innovation Passport designation for deucrictibant in the UK reflects regulatory recognition of deucrictibant's innovation for better treatment options for people living with HAE."
DonCorleone77
Posted - 7 months ago
$PHVS 1 of 2 - Pharvaris reports Q4 EPS (EUR 0.74) vs. (EUR 1.16) last year Cash and cash equivalents were approximately EUR 391M as of December 31, 2023, compared to approximately EUR 162M for December 31, 2022. "2024 is off to a strong start, supported by the incredible momentum we built in an impressive 2023-driven by a second positive data readout of deucrictibant that was validated by the support of our investors," said Berndt Modig, Chief Executive Officer of Pharvaris. "At the start of the year, the lift of the remaining hold on the prophylaxis program in the U.S. allowed us to progress with the global Phase 3 clinical development plans for deucrictibant for prevention of HAE attacks. As we move toward the initiation of CHAPTER-3, we hope to realize the promise of the proof-of-concept CHAPTER-1 data, which support deucrictibant's potential to be a best-in-class oral prophylactic therapy....
Stock_Titan
Posted - 7 months ago
$PHVS Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
https://www.stocktitan.net/news/PHVS/pharvaris-reports-fourth-quarter-and-full-year-2023-financial-zfeemq8d0c8e.html
CandlesBACKEDSECURITIES
Posted - 7 months ago
$PHVS $BCRX who from JMP Securities is covering Pharvaris?? Liisa Bayko? What does she think
CandlesBACKEDSECURITIES
Posted - 7 months ago
$PHVS $BCRX so this is the company that could bankrupt BCRX? Superior oral HAE product???
Stock_Titan
Posted - 7 months ago
$PHVS Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
https://www.stocktitan.net/news/PHVS/pharvaris-to-present-deucrictibant-clinical-data-at-the-ciic-spring-omq0ig66fd0i.html
DailyStocksPicks
Posted - 03/24/24
Acelyrin ($SLRN): Acelyrin’s stock is perceived as oversold due to the divergence between its clinical advancements, institutional support, and analysts' optimistic forecasts versus its recent stock performance. Despite facing downward pressure, the company’s engagement in critical clinical trials and backing from notable institutional investors suggest an underappreciation of its value and potential, especially when considering its innovative pipeline in addressing unmet medical needs. $TYRA, $ZYME, $PHVS, $WVE For More Details: https://youtu.be/yeL_bMBSsNQ
briefingcom
Posted - 8 months ago
$PHVS: Pharvaris N.V. announces phase 3 clinical study design for recently initiated RAPIDe-3 Study, and presents quality-of-life improvement and caregiver behavior data at Two Recent HAE Congresses https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240318065141PHVS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
